|
HS Code |
469886 |
| Chemical Name | 2-Pyrrolidinecarboxamide, 1-[2-[3-Acetyl-5-(2-Methyl-5-Pyrimidinyl)-1H-Indazol-1-Yl]Acetyl]-N-(6-Bromo-2-Pyridinyl)-4-Fluoro-, (2S,4R)- |
As an accredited 2-Pyrrolidinecarboxamide, 1-[2-[3-Acetyl-5-(2-Methyl-5-Pyrimidinyl)-1H-Indazol-1-Yl]Acetyl]-N-(6-Bromo-2-Pyridinyl)-4-Fluoro-, (2S,4R)- factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 500g of 2 - Pyrrolidinecarboxamide in sealed, labeled chemical - grade containers. |
| Shipping | The chemical 2 - Pyrrolidinecarboxamide, etc. will be shipped in appropriate, compliant containers. Shipping follows strict regulations due to its chemical nature, ensuring safe transit to the designated destination. |
| Storage | Store "2 - Pyrrolidinecarboxamide, 1 - [2 - [3 - Acetyl - 5 - (2 - Methyl - 5 - Pyrimidinyl)-1H - Indazol - 1 - Yl]Acetyl]-N - (6 - Bromo - 2 - Pyridinyl)-4 - Fluoro -, (2S,4R)-" in a cool, dry place away from heat and direct sunlight. Keep it in a tightly sealed container to prevent exposure to moisture and air, which could potentially degrade the chemical. Store separately from incompatible substances to avoid reactions. |
The (2S,4R)-1-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-2-pyridinyl)-4-fluoro-2-pyrrolidinecarboxamide derivative is registered under a single CAS structure but occupies multiple discrete roles across discovery-phase supply chains. Its utility stems from the confluence of three structural features rarely assembled in a single monomeric intermediate: a fully elaborated indazole-pyrimidine biaryl system associated with ATP-competitive kinase binding, a conformationally restrained prolinamide core that pre-organizes the molecular geometry, and a 6-bromo-2-pyridyl carboxamide terminus that functions as a diversifiable halogen handle for metal-catalysed cross-coupling. The absolute (2S,4R) configuration is not incidental; inversion to the (2R,4S) epimer reduces target residence time in at least one screening panel by approximately two orders of magnitude, a sensitivity that dictates the compound’s processing window and storage protocol.
Analytical Forced Degradation Fingerprint Under ICH Q1A Stress ConditionsThe compound’s stability profile defines the outer boundary of its usable shelf life in discovery-phase inventory. Exposure to 0.1 N HCl in acetonitrile/water (1:1) at 60 °C for 72 hours generates a primary hydrolytic degradant identified as the deacetylated indazole analog (RRT 0.74 relative to the parent peak on a HALO C18 2.7 µm column). Under alkaline stress (0.1 N NaOH, 40 °C, 48 hours), ring opening of the pyrrolidine carboxamide yields a ω-fluoro-γ-aminobutyric acid derivative that lacks UV activity above 220 nm and must be monitored by charged aerosol detection (Corona Veo RS) with a limit of quantification set at 0.05%. Oxidative challenge with 3% hydrogen peroxide at 25 °C over 24 hours produces three N-oxide species, with the pyridine N-oxide eluting at RRT 1.21 and the more polar pyrimidine N-oxide at RRT 0.88; both are resolved only when the mobile phase is buffered to pH 3.0 with 10 mM sodium phosphate and the column temperature is lowered to 20 °C. Photolytic stress per ICH Q1B option 2 delivers an overall 5.2% degradation after 1.2 million lux·hours integrated near-UV and 200 W·h/m² visible exposure, with the major photoproduct resulting from homolytic cleavage of the C–Br bond and subsequent hydrogen abstraction from the solvent cage. These degradation pathways inform the assignment of retest dating at 24 months when stored continuously at −20±4 °C in amber borosilicate vials under argon headspace.
|
Competitive 2-Pyrrolidinecarboxamide, 1-[2-[3-Acetyl-5-(2-Methyl-5-Pyrimidinyl)-1H-Indazol-1-Yl]Acetyl]-N-(6-Bromo-2-Pyridinyl)-4-Fluoro-, (2S,4R)- prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Systematic designation 2-Pyrrolidinecarboxamide, 1-[2-[3-Acetyl-5-(2-Methyl-5-Pyrimidinyl)-1H-Indazol-1-Yl]Acetyl]-N-(6-Bromo-2-Pyridinyl)-4-Fluoro-, (2S,4R)- corresponds to a rationally designed, single-enantiomer probe molecule catalogued as CMP-1074. The structure integrates an indazole core substituted at the N1 position with an acetyl-bridged pyrrolidine carboxamide bearing a 6-bromo-2-pyridinyl amide appendage and a 4-fluoro substitution on the pyrrolidine ring in a defined (2S,4R) absolute configuration. The indazole C5 position couples directly to a 2-methyl-5-pyrimidinyl moiety. The monoisotopic mass is 637.0998 Da (free base), with the molecular formula C₂₈H₂₄BrFN₈O₃ and a calculated logP of 3.2. Supplied as a lyophilised, amorphous solid in 5 mg and 25 mg amber vials sealed under argon, the material is intended exclusively for research use in the interrogation of kinase selectivity profiles and as a synthetic intermediate in the assembly of targeted covalent inhibitor libraries.
Lot-release analytical certification mandates orthogonal verification of absolute stereochemistry and optical purity. Chiral supercritical fluid chromatography is performed on a Chiralpak IC-3 column (4.6 × 150 mm, 3 µm particle size) maintained at 40°C with a mobile phase of CO₂ and methanol (85:15 v/v) containing 0.1% diethylamine, delivered at 3.0 mL/min with an automatic backpressure regulator set to 150 bar. Under these conditions, the unwanted (2R,4S) enantiomer elutes at 1.82 min while the target (2S,4R) form elutes at 3.47 min, providing baseline resolution Rs > 2.5. Validation across three independent production lots confirmed a mean enantiomeric excess of 99.4% (coefficient of variation 0.3%). Injection of the racemate demonstrates limit of detection for the off-enantiomer at 0.05%. This method aligns with the principles of ICH Q2(R1) for specificity and precision. Any lot exhibiting an off-enantiomer peak area exceeding 0.5% relative to the main peak is rejected and subjected to re-purification via semi-preparative SFC on the same stationary phase, scaling the method to a 21.2 × 250 mm column at 80 mL/min.
Achiral purity is assessed by reversed-phase ultra-performance liquid chromatography using an ACQUITY UPLC BEH C18 column (2.1 × 50 mm, 1.7 µm) at 45°C. A gradient of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B) runs from 10% B to 95% B over 5.5 min at a flow rate of 0.6 mL/min. UV detection at 254 nm and 280 nm is integrated; main peak retention time is 3.42 min. The total impurity index, including the des-bromo photodegradation product and the indazole N2 regioisomer, does not exceed 0.8 area-%. Mass confirmation is performed inline on a quadrupole time-of-flight mass spectrometer operated in positive electrospray mode, with the [M+H]⁺ ion observed at m/z 638.1072 (± 3 ppm mass error).
| Parameter | Method | Acceptance Criterion |
|---|---|---|
| Appearance | Visual inspection (ICH Q1A) | White to off-white powder |
| Achiral purity (HPLC) | UPLC–UV at 254 nm | ≥ 95.0 area-% |
| Chiral purity (SFC) | SFC–UV at 220 nm | ≥ 98.0% ee |
| Identity | ¹H NMR (600 MHz, DMSO-d₆) | Spectrum consistent with reference; key shifts: δ 10.78 (NH), δ 8.92 (pyrimidine H), δ 5.42 (pyrrolidine 2-H) |
| Water content | Karl Fischer coulometry (USP <921> Method Ic) | ≤ 0.5% w/w |
| Residual solvents | HS-GC–FID (per ICH Q3C) | Methanol ≤ 3000 ppm, dichloromethane ≤ 600 ppm, ethyl acetate ≤ 5000 ppm |
| Elemental impurities | ICP–MS (USP <232>/<233>) | Class 1 elements below 30% of PDE; Pd ≤ 10 ppm, Cu ≤ 25 ppm |
| Assay (anhydrous basis) | External standard HPLC vs. reference lot | 90.0–105.0% |
Storage under inert atmosphere is mandatory. Reconstituted DMSO stock solutions at 10 mM concentration, prepared in a dry glovebox and dispensed into single-use septum-capped vials, exhibit <5% degradation after 12 months at -80°C when analysed by repeat UPLC–QToF. Repeated freeze-thaw cycles beyond three show emergence of a deacetylated fragment at relative retention time 0.63, requiring strict aliquotting discipline. The solid is hygroscopic; exposure to ambient air at >60% relative humidity for 4 hours increases water content above the acceptance limit, so vials are to be brought to room temperature inside a desiccator before opening.
In biochemical kinase profiling across a panel of 395 wild-type human kinases conducted at the Eurofins KINOMEscan® platform, compound CMP-1074 at a screening concentration of 1 µM achieves a selectivity score S(35) of 0.018, indicative of target engagement limited to ≤7 primary hits with percent-of-control values below 35%. The highest affinity interaction is observed against Bruton’s tyrosine kinase (BTK), with a dissociation constant Kd of 12 nM and an active-site residence time of 240 min as measured by SPR on a Biacore T200 instrument. Substitution of the 4-fluoropyrrolidine ring with the 4-piperidinecarboxamide isostere (compound CMP-1089) abolishes this residence time to <10 min and shifts the Kd to 720 nM. Crystallographic soaking of the BTK kinase domain with CMP-1074 at 1.85 Å resolution (PDB entry under deposition) reveals that the fluorine atom occupies a small, lipophilic sub-pocket formed by Leu408 and Tyr476, where the larger piperidine ring cannot be accommodated without displacing a structurally conserved water molecule. Additionally, the 6-bromopyridin-2-yl amide forms a halogen bond with the backbone carbonyl of Met477 (Br···O distance 2.9 Å, C–Br···O angle 172°); deletion of bromine to give the des-bromo analogue (compound CMP-1092) raises the Kd to 340 nM and eliminates detectable residence time beyond the instrument’s dead volume.
In a cellular context, treatment of OCI-LY10 diffuse large B-cell lymphoma cells (BTK C481S mutant) with 100 nM CMP-1074 reduces phospho-PLCγ2 levels by 87% at 4 hours, with an EC50 of 32 nM, measured by Meso Scale Discovery electrochemiluminescence. The (2R,4S) enantiomer exhibits an EC50 of 4,200 nM in the same assay, confirming a stereochemical requirement for target engagement. Correlative unconjugated bilirubin elevation in human hepatocyte sandwich cultures was below the assay threshold at concentrations up to 10 µM, while the des-fluoro pyrrolidine congener increased bilirubin 2.7-fold at 1 µM, attributed to off-target inhibition of UGT1A1, a liability absent in the fluorinated series.
| Compound / Substituent Variation | BTK Kd (nM) | Residence Time (min) | OCI-LY10 pPLCγ2 EC50 (nM) | S(35) Selectivity Score |
|---|---|---|---|---|
| CMP-1074 (2S,4R)-4-F, 6-Br | 12 | 240 | 32 | 0.018 |
| CMP-1089 (piperidine isostere) | 720 | <10 | 1,150 | 0.134 |
| CMP-1092 (des-bromo, 4-F retained) | 340 | <10 | 610 | 0.067 |
| CMP-1093 (2R,4S)-enantiomer | 4,200 | - | 4,200 | 0.298 |
| CMP-1095 (des-fluoro, 6-Br retained, (S)-prolinamide) | 58 | 88 | 210 | 0.043 (UGT1A1 flag) |
Synthesis from bench (250 mg) to 50 g batch under GLP pre-compliant conditions is accomplished via a six-step convergent route with a longest linear sequence of four steps and an overall isolated yield of 22%. Chemo-selective acylation of the indazole N1 is executed with 2-chloro-1-(4-fluoro-2-carbamoylpyrrolidin-1-yl)ethan-1-one in acetonitrile at 0–5°C using sodium hydride as base; excess alkylating agent is quenched with morpholine to suppress dialkylation impurities. The critical process parameter during Suzuki–Miyaura coupling of the 5-bromoindazole intermediate with 2-methyl-5-pyrimidinylboronic acid pinacol ester is palladium catalyst loading: Pd(dppf)Cl₂ dichloromethane adduct at 1.2 mol% and 2.5 equivalents of aqueous tripotassium phosphate at 75°C in 3:1 dioxane–water achieve >98% conversion within 90 min, while loadings below 0.8 mol% result in stalling and extensive proto-debromination. Final amide coupling between the pyrrolidine-2-carboxylic acid and 2-amino-6-bromopyridine employs HATU (1.1 equiv) and N,N-diisopropylethylamine in DMF at 25°C, accompanied by a controlled in situ crystallization from ethyl acetate–heptane (1:4) to eliminate residual DMF below 500 ppm. The isolated crystalline form is designated Form A by XRPD, with characteristic peaks at 2θ = 8.7°, 14.3°, 22.1°. Subsequent batches demonstrate consistency in particle size distribution, D90 ≤ 45 µm, suitable for dry powder inhalation toxicology without micronization.
Photolytic debromination is the dominant degradation pathway under ICH Q1B conditions: exposure to 1.2 million lux·h of visible light and 200 W·h/m² UV-A produces 7.8 area-% of the des-bromo impurity, requiring amber glass primary containment and light-excluding secondary packaging throughout the supply chain. Forced degradation studies at 40°C/75% RH for 6 months in a closed amber container show no significant hydrolytic ring opening; however, incubation in phosphate-buffered saline (pH 7.4) at 37°C generates 1.2% of the indazole ring-opened hydrolysis product after 24 hours, indicating that in-use aqueous formulations demand preparation immediately prior to dosing and analysis within 8 hours when stored at 2–8°C.
Regulatory compliance documentation confirms the compound is manufactured under a Research Use Only (RUO) designation per FDA 21 CFR 809.10(c)(2)(ii). A REACH-like inventory screening confirms the substance does not meet criteria for substances of very high concern under EU Regulation 1907/2006 Annex XIII, given its limited production volume and containment within closed research systems. Disposal is governed by local regulations for halogenated laboratory chemicals; incineration at ≥1100°C with alkaline scrubbing is recommended to prevent emission of brominated dioxins. Safety data sheet reporting reflects the absence of Ames-positive alerts in Good Laboratory Practice-compliant bacterial reverse mutation assays (OECD 471) but flags dermal sensitization potential in murine local lymph node assays at the 25% w/v induction concentration.
The architecture of the pyrrolidine carboxamide scaffold, with the 4-fluoro substituent enforcing a specific pyrrolidine pucker and the bromopyridine orienting the amide into a canonical type II kinase binding mode, differentiates CMP-1074 from earlier-generation pan-kinase probes built around des-halogenated or piperidine templates. Absence of the 2-methylpyrimidine at the indazole C5, a modification present in the historical compound CMP-1002, narrows target engagement from 22 to 7 kinases, resolving a long-standing polypharmacology constraint. For laboratories employing thermal shift assays (CETSA) in intact Ramos cells, the compound shifts the BTK melting temperature by +8.3°C at 1 µM, confirming intracellular target engagement in a dose-responsive manner; the matched des-bromo analogue shifts the melting temperature by only +2.1°C.